Web Exclusives
Web Exclusives | July 20, 2023
In recognition of the recent announcement by the Centers for Medicare & Medicaid Services (CMS) proposing payment for community health integration services, the Academy of Oncology Nurse & Patient Navigators (AONN+) sees this opportunity as a key initiative to strengthen and accelerate the oncology navigation footprint in every community.
Web Exclusives | June 13, 2023
Analysis of the long-term results of the CodeBreak 100 clinical trial showed that sotorasib demonstrated long-term efficacy, in particular among patients with low initial circulating tumor DNA values.
Web Exclusives | June 13, 2023
A recent study showed that next-generation sequencing testing has superior cost benefit when compared with single-gene testing for multiple cancer types, including non–small cell lung cancer.
Web Exclusives | June 13, 2023
Analysis of the phase 3 study of sotorasib in patients with non–small cell lung cancer found faster time to response compared with docetaxel but a shorter progression-free survival than what was seen in the phase 1/2 trials.
Web Exclusives | June 13, 2023
A recently released study found a significant concordance rate drop between liquid and tissue biopsies via next-generation sequencing when patients had disease progression.
Web Exclusives | May 16, 2023
A recently published case study found sotorasib efficacious and safe as first-line therapy for non–small cell lung cancer harboring the KRAS G12C mutation.
Web Exclusives | May 16, 2023
A Canadian study found that next-generation sequencing identified more mutations, had a faster turnaround time, and was more cost-effective than single-gene testing when used in patients with non–small cell lung cancer.
Web Exclusives | May 16, 2023
A recent review of liquid biopsy studies found it useful in detecting circulating tumor DNA in patients with early and select advanced non–small cell lung cancer.
Web Exclusives | May 16, 2023
A recent review discussed multiple ongoing studies evaluating KRAS G12C inhibitors for the treatment of non–small cell lung cancer harboring the KRAS G12C mutation.
Web Exclusives | April 20, 2023
Bispecific antibodies are unique antibody constructs that simultaneously bind 2 antigens, typically targeting an antigen on myeloma cells and a molecule on an immune cell. By using the patient’s immune system to destroy the malignant plasma cells, bispecific antibodies offer a promising treatment to overcome immunosuppression for patients with relapsing/refractory MM (RRMM).4
Web Exclusives | April 19, 2023
A recent study demonstrates liquid biopsy has high concordance to tissue biopsy in non–small-cell lung cancer, making it an acceptable first-line testing option.
Sotorasib Found to Have Promising Intracranial Activity in Patients with NSCLC with Brain Metastasis
Web Exclusives | April 19, 2023
A small study of patients with non–small-cell lung cancer with brain metastasis showed sotorasib had promising efficacy on brain lesions.
Web Exclusives | April 19, 2023
A recent retrospective analysis of patients with non–small-cell lung cancer harboring KRAS mutations found immune checkpoint inhibitors have benefit in first- and second-line treatment among KRAS subtypes.
Web Exclusives | April 19, 2023
A large retrospective chart review found a short median progression-free survival in patients with non–small-cell lung cancer harboring the KRAS G12C mutation who were treated with docetaxel with or without ramucirumab.
Web Exclusives | March 15, 2023
Biomarker testing is associated with improved overall survival in patients with advanced non–small-cell lung cancer, but disparities in access to testing persist.
Web Exclusives | March 15, 2023
A review of treatments and clinical studies for non–small-cell lung cancer harboring the KRAS G12C mutation finds encouraging overall survival results.
Web Exclusives | March 15, 2023
Palliative care is underused by Black and Hispanic/Latinx patients with advanced non–small-cell lung cancer.
Web Exclusives | March 15, 2023
Evaluation of flat-dose nivolumab plus weight-based ipilimumab in patients with advanced non–small-cell lung cancer and poorer prognosis demonstrates efficacy with a tolerable safety profile.
Web Exclusives | February 21, 2023
A recent review presents updated treatment strategies for patients with non–small-cell lung cancer harboring the KRAS G12C mutation.
Web Exclusives | February 21, 2023
A recent study from the United Kingdom in younger adults with non–small-cell lung cancer found poor survival outcomes in patients without targetable mutations.
Web Exclusives | February 21, 2023
Based on positive results of the KRYSTAL-1 clinical trial, adagrasib was granted accelerated FDA approval for patients with non–small-cell lung cancer harboring the KRAS G12C mutation.
Web Exclusives | February 21, 2023
A recent study assessing the prognostic value of circulating tumor cells in patients with lung cancer found an association with poorer patient outcomes, with more pronounced effect on small-cell lung cancer.
Web Exclusives | January 26, 2023
Sotorasib in a patient with KRAS G12C–mutated lung cancer and brain metastases resolved or shrank brain lesions and improved mental status.
Web Exclusives | January 26, 2023
In patients with non–small-cell lung cancer, broad and rapid genomic profiling are recommended for use at all stages of clinical management to improve patient outcomes.
Web Exclusives | January 26, 2023
Study determines that permanently discontinuing immune checkpoint inhibitors after grade ≥2 immune-related adverse events is an appropriate response for patients with stage IV non–small-cell lung cancer.
Web Exclusives | January 26, 2023
A review of multiple clinical trials in patients with non–small-cell lung cancer and brain metastases finds adagrasib effectively penetrates the central nervous system, resulting in good response rates.
Web Exclusives | December 5, 2022
A guide to the departments and people you should be working with to collect the data pertinent to your navigation program.
Web Exclusives | December 5, 2022
Navigators in the Metric Pilot Study increased the number of palliative care referrals through the use of a symptom assessment tool and worked together to improve the assessment process.
Web Exclusives | December 2, 2022
Despite advantages for molecular testing for non–small-cell lung cancer, the testing rate remains low, with white patients and female patients having a higher likelihood of undergoing molecular testing.
Web Exclusives | December 2, 2022
Maintaining quality of life and independence was found to be a high priority for patients with non–small-cell lung cancer and should be regularly assessed by the care team.
© 2009-2023 DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512